{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016291","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.794125+00:00","generated_at":"2026-06-15T04:36:11.750190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anebulo reports Q3 FY2023 net loss of $2.8M ($0.11/share); cash $14.2M; positive Phase 2 data for ANEB-001","bullets":["Net loss $2.8M ($0.11 per share) vs $1.9M ($0.08) in Q3 FY2022.","Operating expenses $2.9M, up from $1.9M year-over-year.","Cash and cash equivalents $14.2M as of March 31, 2023.","Announced positive complete Phase 2 data for ANEB-001 in acute cannabinoid intoxication.","Type B meeting with FDA scheduled for July 2023 to discuss registrational path."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016291","json":"https://secwatch.observer/filing/0001493152-23-016291.json","markdown":"https://secwatch.observer/filing/0001493152-23-016291.md","text":"https://secwatch.observer/filing/0001493152-23-016291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223016291/0001493152-23-016291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223016291/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:36:11.750190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"259395dd99a93b93a141a463c882cfefa2eb9ecb","claim":"Anebulo Pharmaceuticals, Inc. reported the three months ended March 31, 2023 results: net income $2.8 million, EPS $(0.11) per share.","evidence_excerpt":"Net loss in the third quarter of fiscal 2023 was $2.8 million, or $(0.11) per share, compared with a net loss of $1.9 million, or $(0.08) per share, in the third quarter of fiscal 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223016291/0001493152-23-016291-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"$2.8 million"},{"label":"EPS","value":"$(0.11) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}